कंपनी का अवलोकन
Aquestive Therapeutics, Inc. operates primarily within the healthcare sector, specifically functioning as a drug manufacturer focused on specialty and generic pharmaceutical products in both the United States and international markets. The company's core business involves developing and commercializing unique formulations such as Libervant, a buccal soluble film of diazepam for seizure treatment, and Suboxone, a sublingual film combining buprenorphine and naloxone for opioid use disorder management. This specialized operational focus places the firm in a niche segment of the broader pharmaceutical industry where regulatory hurdles and clinical trial requirements are significant. As of the latest data, the company maintains a market capitalization of $508.93M, generates annual revenue of $44.55M, and employs a workforce of 147 individuals. These financial figures indicate that Aquestive Therapeutics is a mid-cap entity with a relatively compact revenue stream compared to large-cap pharmaceutical giants, suggesting a position that relies heavily on the successful commercialization of its specific patented drug formulations to drive future scaling.
वित्तीय स्वास्थ्य
The company reported a total revenue of $44.55M over the trailing twelve months, yet this revenue generated a net income of -$83,784,000, revealing a substantial gap that indicates a high-cost structure typical of early-stage biopharmaceutical firms with significant research and development expenditures. Concurrently, the EBITDA stood at -$70,477,000, further highlighting the operational losses incurred before interest, taxes, and non-cash items like depreciation. The firm's free cash flow was -$29,235,376, which signifies a current burn rate that limits immediate financial flexibility and necessitates careful capital management to sustain operations without external financing. Profitability metrics reflect this challenge, with a gross margin of 58.3% indicating efficient production costs, but an operating margin of -221.6% and a profit margin of -188.1% demonstrating that general and administrative expenses, along with R&D investments, are currently outpacing gross profitability. On the balance sheet, the company holds $121.17M in cash against $42.48M in debt, providing a net cash position, though the debt-to-equity ratio is listed as N/A due to accounting conventions for negative equity or specific reporting standards. The current ratio of 3.13 suggests a robust short-term liquidity position, as the company possesses more than three times the current assets required to cover its short-term liabilities. Return on Equity and Return on Assets metrics are reported as N/A and -33.9% respectively, where the negative ROA indicates that the company's assets are currently generating a loss relative to its total asset base, reflecting the heavy investment phase of its business model.
मूल्यांकन आकलन
Valuation multiples for Aquestive Therapeutics, Inc. reflect its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -7.19, implying that market expectations do not anticipate immediate earnings turnaround in the near term. The price-to-book ratio is recorded at -15.11, a negative figure that indicates the market prices the stock below the book value of its assets, a common characteristic for biotech firms with limited tangible assets relative to their intellectual property portfolio. Alternative valuation metrics such as the price-to-sales ratio of 11.43 and an EV/EBITDA of -6.11 suggest that investors are pricing the company based on future growth potential in its drug pipeline rather than current earnings or asset backing. The stock has demonstrated significant volatility within its trading range, with a 52-week high of $7.55 and a 52-week low of $2.12, indicating a wide spread where the current price sits below the recent peak but above the bottom of the range. The beta value of 1.53 reveals that the stock's price volatility is substantially higher than the broader market, moving approximately 53% more aggressively than the S&P 500 in response to market movements.
Growth & Income
Revenue growth for the trailing twelve months stands at 9.7%, indicating a successful expansion in sales volume or market penetration, while earnings growth is listed as N/A due to the company's ongoing net losses. The disparity between positive revenue growth and negative earnings growth implies that top-line expansion is currently being funded by heavy expenditures rather than immediate profitability, a standard dynamic for pharmaceutical companies in the development or launch phase of new therapies. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flow is retained within the company to fund operations, R&D, and strategic growth initiatives rather than being distributed to shareholders. Consequently, the overall growth and income profile of Aquestive Therapeutics is characterized by capital appreciation potential through reinvestment in its drug portfolio rather than reliance on dividend income or consistent earnings expansion in the current fiscal period.